drugset / Trial / NCT01338610

ESBA105 in Patients With Severe Dry Eye

NCT01338610 ↗

Phase 2 Completed 334 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global Visual Analog Scale (VAS) discomfort score.

Timeline

Start
2011-06
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ESBA105 Monoclonal antibody — Other

Indications